drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR-T)
drug_description
Autologous gene-modified T cells engineered to express a CAR targeting BCMA, depleting BCMA-positive plasma cells/plasmablasts to reduce pathogenic autoantibody production in MDR-SRNS.
nci_thesaurus_concept_id
C176023
nci_thesaurus_definition
A preparation of CAR-T cells that targets the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA;TNFRSF17).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor specific for BCMA. On recognizing BCMA on plasma cells/plasmablasts, the CAR-T cells become activated and kill these BCMA-positive cells via cytotoxic mechanisms, depleting antibody-secreting cells and reducing pathogenic autoantibody production in MDR-SRNS.
drug_name
Anti-BCMA CAR-T cells
nct_id_drug_ref
NCT06553898